Physician profile
Melissa A John
NPI 1013295831
$2,982.80
in general payments reported to CMS, 2019-2025
24 companies · $850 in 2025
The $850 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $50.26 · 2021: $459 · 2022: $423 · 2023: $432 · 2024: $586 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $760.35 | 2020-2025 | |
| Novo Nordisk INC | $550.09 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $300.12 | 2019-2025 | Veozah |
| Abbvie INC. | $294.02 | 2021-2025 | |
| Lilly USA, LLC | $196.77 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Exact Sciences Corporation | $142.06 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $89.95 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $67.97 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $55.16 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $54.76 | 2022-2023 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $52.41 | 2022 | |
| Merck Sharp & Dohme LLC | $52.22 | 2021-2024 | Lagevrio, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.68 | 2023-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.25 | 2019-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $44.03 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.55 | 2019 | |
| Axsome Therapeutics, INC. | $32.97 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $29.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.28 | 2019-2021 | |
| Harmony Biosciences LLC | $26.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.37 | 2023 | |
| Biogen, INC. | $16.18 | 2023 | Spinraza |
| Daiichi Sankyo INC. | $16.00 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.